Exagen Inc. (XGN)

NASDAQ: XGN · IEX Real-Time Price · USD
2.80
+0.09 (3.32%)
Oct 3, 2022 4:00 PM EDT - Market closed
3.32%
Market Cap 45.53M
Revenue (ttm) 44.30M
Net Income (ttm) -37.81M
Shares Out 16.26M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,509
Open 2.80
Previous Close 2.71
Day's Range 2.79 - 2.98
52-Week Range 2.65 - 14.85
Beta 1.03
Analysts Buy
Price Target 12.50 (+346.4%)
Earnings Date Nov 8, 2022

About XGN

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue dis... [Read more...]

Industry Health Care Providers & Services
IPO Date Sep 19, 2019
CEO Fortunato Rocca
Employees 219
Stock Exchange NASDAQ
Ticker Symbol XGN
Full Company Profile

Financial Performance

In 2021, Exagen's revenue was $48.30 million, an increase of 15.07% compared to the previous year's $41.98 million. Losses were -$26.85 million, 60.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for XGN stock is "Buy." The 12-month stock price forecast is 12.5, which is an increase of 346.43% from the latest price.

Price Target
$12.5
(346.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting

SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College...

1 week ago - GlobeNewsWire

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory Universit...

1 month ago - GlobeNewsWire

Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of -41.82% and 25.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validat...

1 month ago - GlobeNewsWire

Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual Growth ...

2 months ago - GlobeNewsWire

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the ...

2 months ago - GlobeNewsWire

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled ...

SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing enables de...

2 months ago - GlobeNewsWire

Exagen Inc. Expands Coverage with MediNcrease

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC's...

3 months ago - GlobeNewsWire

Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth Stock...

4 months ago - GlobeNewsWire

Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® C...

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered servi...

4 months ago - GlobeNewsWire

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has prov...

4 months ago - GlobeNewsWire

Exagen Inc. Reports First Quarter 2022 Results

Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly Volume in March Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CT...

4 months ago - GlobeNewsWire

Exagen Announces Five-Week Campaign for Lupus Awareness Month

SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-...

5 months ago - GlobeNewsWire

Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022

SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after th...

5 months ago - GlobeNewsWire

Exagen Inc. to Participate in Investor Summit Group's Q2 Conference

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group's Q2 Conference, w...

5 months ago - GlobeNewsWire

Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement w...

6 months ago - GlobeNewsWire

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as an in...

6 months ago - GlobeNewsWire

Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results

Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross Margin Percent, Adopters, and Ordering Healthcare Providers Six Quarterly Records: AVISE® CTD Volume, Testi...

6 months ago - GlobeNewsWire

Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board

SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB) with...

6 months ago - GlobeNewsWire

Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum

SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Science...

6 months ago - GlobeNewsWire

Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 20...

6 months ago - GlobeNewsWire

Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Sc...

8 months ago - GlobeNewsWire

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patente...

SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a resear...

8 months ago - GlobeNewsWire